Table 3.
Multivariate association of radiological response and survival outcomes with serum miR-122 concentration.
| Outcomes (n) | Total (n) | Univariate HR (95%CI)a | Multivariate HR (95%CI)a,b | |
|---|---|---|---|---|
| 12-week overall response | ||||
| miR122_L group | 5 | 294 | Reference | Reference |
| miR122_H group | 16 | 294 | 3.21 (1.19∼8.63) | 3.22 (1.19∼8.64) |
|
| ||||
| 12-week disease control | ||||
| miR122_L group | 57 | 294 | Reference | Reference |
| miR122_H group | 83 | 294 | 1.47 (1.08∼1.97) | 1.48 (1.08∼1.98) |
|
| ||||
| 12-week PFS | ||||
| miR122_L group | 57 | 294 | Reference | Reference |
| miR122_H group | 83 | 294 | 1.47 (1.08∼1.97) | 1.48 (1.08∼1.98) |
|
| ||||
| 12-week OS | ||||
| miR122_L group | 255 | 294 | Reference | Reference |
| miR122_H group | 283 | 294 | 1.12 (1.07∼1.17) | 1.12 (1.07∼1.18) |
|
| ||||
| 24-week overall response | ||||
| miR122_L group | 1 | 294 | Reference | Reference |
| miR122_H group | 8 | 294 | 8.01 (1.01∼63.57) | 8.02 (1.01∼63.58) |
|
| ||||
| 24-week disease control | ||||
| miR122_L group | 11 | 294 | Reference | Reference |
| miR122_H group | 27 | 294 | 2.46 (1.24∼4.87) | 2.47 (1.24∼4.88) |
|
| ||||
| 24-week PFS | ||||
| miR122_L group | 11 | 294 | Reference | Reference |
| miR122_H group | 27 | 294 | 2.46 (1.24∼4.87) | 2.47 (1.24∼4.88) |
|
| ||||
| 24-week OS | ||||
| miR122_L group | 203 | 294 | Reference | Reference |
| miR122_H group | 241 | 294 | 1.19 (1.09∼1.31) | 1.20 (1.09∼1.32) |
aPFS: progression-free survival; OS: overall survival; HR: hazard ratio; CI: confidence interval. bThe multivariate COX model was adjusted by gender, age, annual income, HBeAg, HBV-DNA, serum albumin, serum total bilirubin, serum fetoprotein, ECOG score, maximum diameter of tumor, number of tumors, extent of tumor, portal vein invasion, and hepatic vein invasion.